Prescient Therapeutics (ASX:PTX) resolved the technical difficulties facing its OmniCAR program by creating a new generation of improved variants, according to a Thursday Australian bourse filing.
OmniCAR is a CAR(chimeric antigen receptor)-cell platform, that enables controllable T-cell activity and multi-antigen targeting with a single-cell product.
It observed that OmniCAR T-cells unarmed with antigen binders were demonstrating unexpected activity, which ran counter to "the modular, controllable thesis" of the program.
It developed several OmniCAR variants over 2024 in collaboration with the Peter McCallum Cancer Center and Australia's Commonwealth Scientific and Industrial Research Organization, that overcame the issues observed with the previous OmniCAR version in preliminary in vitro and in vivo testing.
When armed with binders, these new variants demonstrated highly effective tumor-killing activity in mice with Her2-positive tumors. The duration of efficacy was more than that of the previous version of the platform.
It will further evaluate these variants in 2025.
The firm's shares rallied 13% in trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.